Since 2015, Dr. Toren has worked as a clinician-scientist in the Department of Surgery at Laval University, where his laboratory focuses on translational prostate cancer research. He completed his medical training at Queen’s University in Kingston, Ontario, urology residency and a clinical uro-oncology fellowship at the University of Toronto. Subsequently, he completed a two-year research fellowship at the Vancouver Prostate Centre, under the mentorship of Dr. Martin Gleave. Concurrently, he enrolled in, and recently completed a doctorate in experimental medicine in Dr. Amina Zoubeidi’s laboratory.

The influence of sex steroids on the tumor environment

Androgens and estrogens are important to prostate cancer progression and treatment resistance. Through the analysis of various sex steroids such as testosterone and estrogens, we seek to better understand the hormonal changes which occur following treatment in prostate cancer patients. Further, we seek to understand how differences in these levels between patients may be used to classify them for optimal treatments and understand resistance patterns. We use laboratory models to understand the effect of sex steroids on the local immune environment and production of cytokines regulating the survival and growth of prostate cancer.

Extracellular vesicles as biomarkers

Extracellular vesicles, such as exosomes, are tiny parts of cells which may be detected in many biological fluids, including urine and blood. Using samples from prostate cancer patients, we seek to optimize isolation, enumeration, and characterization techniques. Versatile and containing a significant amount of information pertinent to cancer type and function, these tiny particles may eventually be used to monitor information about responsiveness to treatments through a simple blood test.

L'Hôtel-Dieu de Québec
6, rue McMahon
0877
Québec, Québec
Canada G1R 2J6
53 entries « 1 of 6 »

Boibessot C, Joncas FH, Park A, Berrehail Z, Pelletier JF, Gris T, Bergeron A, Toren P

Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs.

Journal Article

Sci Rep, 11 (1), 2021.

Abstract | Links:

Kourbanhoussen K, Joncas FH, D Wallis CJ, Hovington H, Dagenais F, Fradet Y, Guillemette C, Lacombe L, Toren P

Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer.

Journal Article

Asian J Androl, 2021.

Abstract | Links:

Tremblay S, Summers-Trasiewicz L, Pouliot F, Crook JM, Ding K, Klotz L, Toren P

Reply by Authors.

Journal Article

J Urol, 206 (5), 2021.

| Links:

Kourbanhoussen K, McMartin C, Lodde M, Zlotta A, Bryan RT, Toren P

Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer.

Journal Article

Eur Urol Focus, 7 (5), 2021.

Abstract | Links:

Otis-Chapados S, Goulet CR, Dubois G, Lavallée É, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F

F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy.

Journal Article

Can Urol Assoc J, 15 (10), 2021.

Abstract | Links:

Chahine S, Toren P

Images - Para-aortic lymphatic ectasia suggestive of testicular cancer retroperitoneal metastasis.

Journal Article

Can Urol Assoc J, 15 (1), 2021.

| Links:

Al-Hogbani M, Duguay J, Wagner DC, Haferkamp A, Joubert P, Frees S, Rendon R, Power N, Perigny M, Toren P

Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors.

Journal Article

Urol Oncol, 39 (5), 2021.

Abstract | Links:

Toren P, Brisson H, Simonyan D, Hovington H, Lacombe L, Bergeron A, Fradet Y

Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival.

Journal Article

World J Urol, 39 (5), 2021.

Abstract | Links:

Al-Hogbani M, Gilbert S, Lodde M, Fradet Y, Toren P

Does 5-alpha Reductase Inhibitor Use Improve The Efficacy of Intravesical Bacille Calmette-Guerin (BCG) for Non-muscle Invasive Bladder Cancer?

Journal Article

Bladder Cancer, 6 (1), 2020.

| Links:

Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P

Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study.

Journal Article

Eur Urol Oncol, 3 (3), 2020.

Abstract | Links:

53 entries « 1 of 6 »
Signaler des ajouts ou des modifications

Active projects

  • Development of next-generation biomarkers for prostate cancer treatment, from 2019-07-01 to 2021-12-31
  • Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30

Recently finished projects

  • (FRSQ 91289) Androgen-receptor dependent changes in human bladder cancer macrophages.” , from 2019-09-04 to 2021-09-03
  • Enhancing bladder cancer immunotherapy efficacy in men using bicalutamide, from 2018-12-01 to 2019-11-30
  • Investiguer les facteurs moléculaires qui influencent la progression du cancer de la prostate., from 2016-07-01 to 2020-06-30
  • Sex steroids as modulators of the prostate cancer immune microenvironment, from 2018-09-01 to 2021-08-31
Data provided by the Université Laval research projects registery